Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Traws Pharma (TRAW) FCF Margin (2016 - 2025)

Traws Pharma (TRAW) has disclosed FCF Margin for 14 consecutive years, with 218.77% as the latest value for Q2 2025.

  • On a quarterly basis, FCF Margin rose 1706544.0% to 218.77% in Q2 2025 year-over-year; TTM through Sep 2025 was 684.01%, a 1267085.0% increase, with the full-year FY2024 number at 14796.46%, down 685575.0% from a year prior.
  • FCF Margin was 218.77% for Q2 2025 at Traws Pharma, up from 9538.6% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 218.77% in Q2 2025 to a low of 20133.33% in Q3 2024.
  • A 5-year average of 8744.54% and a median of 7755.89% in 2022 define the central range for FCF Margin.
  • Peak YoY movement for FCF Margin: tumbled -1229298bps in 2024, then soared 1706544bps in 2025.
  • Traws Pharma's FCF Margin stood at 7616.07% in 2021, then rose by 9bps to 6935.71% in 2022, then fell by -14bps to 7910.71% in 2023, then rose by 9bps to 7214.29% in 2024, then soared by 97bps to 218.77% in 2025.
  • Per Business Quant, the three most recent readings for TRAW's FCF Margin are 218.77% (Q2 2025), 9538.6% (Q1 2025), and 7214.29% (Q4 2024).